Evidence map›Paper›PMID 33354748›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2021

The Role of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi: A Meta-Analysis and Systematic Review.

Abdullah Al-Abcha, Khader Herzallah, Yehia Saleh, Mark Mujer, Ola Abdelkarim, Mahmoud Abdelnabi, Abdallah Almaghraby, George S Abela

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Abdullah Al-AbchaDepartment of Internal Medicine, Michigan State University, East Lansing, MI, USA. alabchaa@msu.edu.ORCID http://orcid.org/0000-0002-9025-7453
Khader HerzallahDepartment of Cardiology, Tufts University, Boston, MA, USA.
Yehia SalehDepartment of Cardiology, Houston Methodist Hospital, Houston, TX, USA.
Mark MujerDepartment of Internal Medicine, Michigan State University, East Lansing, MI, USA.
Ola AbdelkarimDepartment of Cardiology, Alexandria University, Alexandria, Egypt.
Mahmoud AbdelnabiDepartment of Cardiology, Alexandria University, Alexandria, Egypt.
Abdallah AlmaghrabyDepartment of Cardiology, Alexandria University, Alexandria, Egypt.
George S AbelaDepartment Cardiology, Michigan State University, East Lansing, MI, USA.
Alexandria University · EGMichigan State University · USMethodist Hospital · USTufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDirect oral anticoagulants (DOACs) have a well-established role in the treatment of deep vein thrombosis and pulmonary embolism and in the reduction of thromboembolism in nonvalvular atrial fibrillation. However, limited evidence supports their role in patients with left ventricular thrombi.

methodsThe PubMed, EMBASE, and Cochrane databases were searched for relevant articles published from inception to 1 August 2020. We included studies evaluating the effect of DOACs versus vitamin K antagonists (VKAs) in patients with left ventricular thrombi. The primary outcome was thrombus resolution, and the secondary outcomes were major bleeding and stroke or systemic embolization (SSE).

resultsFive retrospective observational studies were included, with a total of 857 patients. VKAs and DOACs had a similar rate of thrombus resolution (odds ratio [OR] 0.97; 95% confidence interval [CI] 0.57-1.65; p = 0.90). Our analysis also demonstrated a similar rate of major bleeding (OR 0.62; 95% CI 0.27-1.44; p = 0.27) and SSE (OR 1.86; 95% CI 0.99-3.50; p = 0.05) between the two treatment groups.

conclusionIn patients with left ventricular thrombi, DOACs and VKAs are associated with similar rates of thrombus resolution, major bleeding, and SSE.

Indexed as

AnticoagulantsFactor Xa InhibitorsHeart VentriclesHemorrhageHumansObservational Studies as TopicRetrospective StudiesThrombosisVitamin KAnticoagulantsFactor Xa InhibitorsVitamin K

Identifiers

PMID33354748
OpenAlexW3117866626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.